CDR Update - Issue 56

In This Issue

• Correction to the Information in the Ambrisentan (Volibris) CEDAC Final Recommendation and Reasons for Recommendation Document

Correction to the Information in the Ambrisentan (Volibris) CEDAC Final Recommendation and Reasons for Recommendation Document

A CEDAC Final Recommendation and Reasons for Recommendation for Ambrisentan (Volibris) was issued by the Canadian Agency for Drugs and Technologies in Health (CADTH) on December 17, 2008. 

It was brought to the attention of the CDR Directorate that the references to the locations of the clinical studies were incorrect. A revised version of the document was issued and posted on the CADTH website (http://www.cadth.ca/index.php/en/cdr/search?status=all&order_field=drug_name&keywords=volibris) on February 5, 2009.

The references to the locations of the clinical studies were corrected in the second and third paragraphs of the document under the heading “Summary of Committee Considerations.”

Clarification of the results for the six-minute walk distance test was provided in paragraph one under the heading “Reasons for Recommendation” and in paragraph two under the heading “Summary of Committee Considerations.”

These changes to the CEDAC Final Recommendation and Reasons for Recommendation document do not alter the Recommendation, nor do they alter the Reasons for Recommendation. CEDAC members have been involved in making these revisions.

CADTH takes all reasonable steps to ensure the accuracy of all documents it issues and regrets any inconvenience to the users of this document resulting from these revisions.